Verastem Oncology, a biopharmaceutical company, announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. These stock options were granted under the Nasdaq inducement grant exception as part of the employees' compensation package upon joining the company. The stock options have an exercise price of $4.29 per share, based on the closing price on July 1, 2025. The vesting schedule for these options begins with twenty-five percent vesting on the one-year anniversary of the employee's hire date, with the remainder vesting quarterly over the next three years, contingent upon continued employment with Verastem Oncology.